BioPharmSignal logoBioPharmSignal

Biotech News

PolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX₁₀₀

PolyPid (PYPD)PolyPidFDA / regulatory

PDUFA target action date of November 28, 2026, approximately one quarter ahead of Company’s previously communicated guidance FDA identified no Filing review issues Acceptance triggers $15 million milestone payment, completing $30 million in upfront and near-term milestone payments under recently

Related news

PYPDPolyPid2026-06-01 12:30 EST

PolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀

PYPDPolyPid2026-03-31 12:30 EST

PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA

View all latest news

PolyPid

Local Controlled-Release Therapeutics PolyPid develops long-acting medicines that release active drugs directly at a surgical or disease site. This approach is intended to improve local exposure while limiting systemic treatment burden. PLEX Technology The PLEX platform embeds drugs within a biodegradable polymer-lipid matrix to control...

Recent company news

PYPDPolyPid2026-10-01 13:15 EST

European Medicines Agency Validates PolyPid’s Marketing Authorization Application for D-PLEX₁₀₀

PYPDPolyPid2026-10-01 12:56 EST

PolyPid Regains European Commercialization Rights for D-PLEX₁₀₀, Expanding Global Commercialization Opportunities

PYPDPolyPid2026-09-15 12:30 EST

PolyPid Announces Participation in Upcoming Fall Investor Conferences

PYPDPolyPid2026-08-12 11:30 EST

PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results

PYPDPolyPid2026-07-30 12:00 EST

PolyPid to Report Second Quarter 2026 Financial Results and Operational Highlights on August 12, 2026

Stock data

Close
5.19 USD
Market cap
93.38M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States